MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
IVA

IVA

Inventiva S.A.

$3.8
0.02
 (0.53%)
Exchange:  NASDAQ
Market Cap:  197.532M
Shares Outstanding:  33.875M
Delayed data
Calculate IVA Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Andrew Obenshain
Full Time Employees:  114
Address: 
50 rue de Dijon
Daix
21121
FR
Website:  https://www.inventivapharma.com
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company’s most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/03/27 — Q4 quarter 2024

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue17,4779,1984,483
Gross Profit17,5009,1981,509.956
EBITDA-102,041-166,525-128,150.429
Operating Income-102,709-97,558-130,946.540
Net Income-110,426-184,212-340,161.126

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets69,561118,967248,879.030
Total Liabilities101,593225,613277,914.667
Total Stockholders Equity-32,032-106,646-29,035.636
Total Debt37,48954,32959,397.708
Cash and Cash Equivalents26,91896,56399,269.731

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-81,614-85,928-100,982.723
Capital Expenditure-540-333-237.255
Free Cash Flow-82,154-86,261-101,219.978
Net Income-110,426-184,212-340,161.126
Net Change in Cash-59,81869,64614,166.522

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)563,758.172Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)563,758.172Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)563,758.172Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-563,758.172Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-563,758.172Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-563,758.172Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)73,641.002Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)73,641.002Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)73,641.002Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)2,118,880.647Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)2,118,880.647Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)2,118,880.647Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.390Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0.390Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.390Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)5Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
108.57
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-6.3
?Enterprise Value
 (TTM)
: 
447.262M  ?EV/FCF
 (TTM)
: 
-4.24
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
18.7  ?ROIC
 (TTM)
: 
-0.66
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
-2.1
?P/B
 (TTM)
: 
-78.18  ?Current Ratio
 (TTM)
: 
3.16

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about IVA valuation

Is Inventiva S.A. (IVA) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Inventiva S.A. (IVA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is IVA a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether IVA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is IVA’s P/E ratio?

You can see IVA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for IVA?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is IVA a good long-term investment?

Whether IVA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

IVA

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.53
MARKETSnap

Trading Metrics:

Open: 3.84   Previous Close: 3.78
Day Low: 3.76   Day High: 3.92
Year Low: 2.85   Year High: 7.98
Price Avg 50: 5.13   Price Avg 200: 5.33
Volume: 829711   Average Volume: 407904

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Inventiva's Speculative Upside Through MASH Is Promising
15-05-2026 18:22
Inventiva's Speculative Upside Through MASH Is Promising
Inventiva to Present Abstracts at the EASL Congress 2026
13-05-2026 02:30
Inventiva to Present Abstracts at the EASL Congress 2026
eGain Launches AI Agent IVA to Deliver Accurate, Conversational Customer Service
06-05-2026 03:56
eGain Launches AI Agent IVA to Deliver Accurate, Conversational Customer Service
Inventiva (NASDAQ:IVA) Shares Gap Down  on Disappointing Earnings
01-04-2026 01:30
Inventiva (NASDAQ:IVA) Shares Gap Down on Disappointing Earnings
Inventiva S.A. (IVA) Q4 2025 Earnings Call Transcript
31-03-2026 16:22
Inventiva S.A. (IVA) Q4 2025 Earnings Call Transcript
Inventiva reports 2025 full year results and provides a business update
30-03-2026 16:11
Inventiva reports 2025 full year results and provides a business update

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read